Novavax to Supply 76 Million COVID-19 Vaccine Doses to Canada

Novavax announced that it has it reached an agreement with the Canadian government to supply the country with up to 76 million doses of its COVID-19 vaccine candidate.

Under the advanced purchase agreement, Novavax will supply the doses of NVX-CoV2373 beginning in the second quarter of 2021, subject to the vaccine’s approval by Health Canada. Financial terms of the agreement were not disclosed.

NVX-CoV2373, which includes the company’s nanotechnology-based Matrix-M adjuvant, is currently in phase 2 clinical testing in the U.S., Australia and South Africa.